Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AdheriumASX:ADR Debt-to-Equity is -1.69 as of Dec. 2025. The stock has 8 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Adherium ranks worse than 141843.83% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Adherium's Debt-to-Equity or its related term are showing as below:
ASX:ADR'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.73 Med: 0.01 Max: 0.53
Current: -1.69
During the past 10 years, the highest Debt-to-Equity Ratio of Adherium was 0.53. The lowest was -1.73. And the median was 0.01.
ASX:ADR's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.23
vs ASX:ADR: -1.69
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Adherium Debt-to-Equity Related Terms
Adherium Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Adherium's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ADR vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Adherium's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adherium Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Adherium's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Adherium's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adherium (ASX:ADR) has a Debt-to-Equity of -1.69 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Adherium and its competitors. According to the industry distribution chart, Adherium ranks #999999 out of 705 companies in the Medical Devices & Instruments industry.
Is Adherium's Debt-to-Equity too high?
Adherium's current Debt-to-Equity is -1.69. Based on the distribution chart, Adherium ranks #999999 out of 705 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Adherium's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Adherium ranks #999999 out of 705 companies for Debt-to-Equity. This places Adherium in the lower half of its industry. The industry median Debt-to-Equity is 0.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Adherium and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adherium's current Debt-to-Equity is -1.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adherium stock overvalued right now?
Based on GuruFocus' analysis, Adherium (ASX:ADR) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.34, compared to a current price of A$0.12 — trading 66.2% below its estimated fair value. The current Debt-to-Equity is -1.69. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Adherium (ASX:ADR), the current Debt-to-Equity is -1.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adherium Ltd is engaged in the development, manufacture, and supply of its Hailie digital health technologies that address sub-optimal medication use and improve health outcomes in chronic disease. It is an international Respiratory eHealth company focused on patient medication adherence, remote monitoring, and data management solutions for patients, payers, and providers. Its geographically segments include New Zealand and Australia, Europe, North America, and Asia. The majority of its revenue comes from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ADR has been successfully added to your 
